Neuroendocrine Tumors
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumors.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2022-11-16EMA Application withdrawn: Sevsury (surufatinib) — Hutchmed Europe B.V.
The EMA withdrawn the application for Sevsury (surufatinib) by Hutchmed Europe B.V. for neuroendocrine tumors.
-
CLINICAL_TRIALS withdrawal · 2017-08-25Clinical Trial Update: Dosimetry Guided PRRT With 90Y-DOTATOC [Phase 2]
A Phase 2 trial evaluating dosimetry-guided peptide receptor radionuclide therapy using 90Y-DOTATOC has been withdrawn. The study covered ne…